Dapagliflozin Improves Diabetic Cardiomyopathy by Modulating the Akt/mTOR Signaling Pathway
- Type
- Retraction
- Notice date
- 6/21/2023 0:00
- Journal
- BioMed Research International
- Publisher
- Hindawi
- Notice DOI
- 10.1155/2023/9765065
- Original paper DOI
- 10.1155/2022/9687345
Reasons
- Concerns/Issues about Data
- Concerns/Issues about Referencing/Attributions
- Concerns/Issues about Peer Review
- Investigation by Journal/Publisher
- Investigation by Third Party
- Unreliable Results and/or Conclusions